SynAct Pharma is a Lund-based biotech company developing novel anti-inflammatory treatments based on melanocortin receptor agonists — a mechanism that harnesses the body's own anti-inflammatory system. The company's lead program targets conditions including rheumatoid arthritis and acute kidney injury. SynAct Pharma raised $1.8M in July 2025 and is conducting clinical studies to advance its pipeline toward market.
synactpharma.comPart of: Skåne Startup map